Clinical Trial Search

Primary: Cumulative Percentage of Patients With an Adverse Event (AE) (Moderate or Severe) on or Before Day 14 Visit — 2.3; 1.01 percentage of participants

Primary: Area Under the Receiver Operating Characteristic Curve (AUC) for the Detection of Atrial Fibrillation — 0.74 probability

Primary: Change From Baseline in Total MCS at Week 6 — -2.6; -2.6 units on a scale — p=0.981

Primary: Number of Subjects With Treatment-emergent Adverse Events — 4; 7; 10; 6 Participants

Primary: Number of Participants With Treatment-related Adverse Events ≥ Grade 2 — 1; 4 Participants

Primary: Maximum Concentration of Percent of Injected Dose in the Whole Brain (Cmax, %ID Brain) of [11C]Osimertinib — 1.465; 1.617; 1.492 percent of radioactive drug

Primary: Change in Cigarettes — 10.2; 7.7 cigarettes per day

Primary: Number of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia and Resolution of Diarrhea (Less Than 3 Loose…

Primary: Subjective Comfort After Contact Lens Insertion — 95 score on a scale

Primary: The Prevalence of Postpartum Depression in the Study Population, as Defined as EPDS Greater Than 10 Out of 30 — 4; 2; 5 Participants

Primary: Number of Evaluable Patients With Dose Limiting Toxicity Events in Phase 1 — 1; 0; 4; 2 Participants

Primary: Part A: Area Under the Concentration-time Curve (AUC) From Zero (Pre-dose) to Time of Last Quantifiable Concentration (AUC[0-t]) Following Administration of Daprodustat…

Primary: Cumulative Incidence Rate of Treatment-related Major Financial Hardship — 71.3; 57.6; 26.6; 26.0 percentage of participants

Primary: Number of Subjects With ≥ 3 Lines Gain in Near Best Distance Corrected Visual Acuity (BDCVA) (at 40 cm) — 10; 12; 10 Participants — p=0.8445

Primary: Mean Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16 — -2.5; -5.2; -6.9; -6.3 abscesses and inflammatory nodules — p=0.0277